Comparison of DPP-4 Inhibitors versus Dapagliflozin in combination with insulin using continuous glucose monitoring in patients with type 2 diabetes mellitus -prospective randomized controlled trial-

Comparison of DPP-4 Inhibitors versus Dapagliflozin in combination with insulin using continuous glucose monitoring in patients with type 2 diabetes mellitus -prospective randomized controlled trial- - Comparison of DPP-4 Inhibitors vs. Dapagliflozin in combination with insulin using CGM

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000015033

Enrollment

Registered

2014-09-03

Start date

2014-09-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus

Interventions

Sitagliptin Vildagliptin Teneligliptin Linagliptin Alogliptin Saxagliptin Dapagliflozin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) patients with type 2 diabetes treating in combination with Inslin and DPP-4 inhibitors 2) HbA1c 6.0-9.0% 3) written informed consent

Exclusion criteria

Exclusion criteria: 1) severe hepatic dysfunction, renal dysfunction, heart failure, 2) history of anaphylaxis of drugs we use, 3) pregnancy, 4) lower than 45ml/min of eGFR, 5)lower Body mass index than 22kg/m2 6) patients who are inadequate to enter this study due to the other reasons by physician's judgments

Design outcomes

Primary

Measure	Time frame
Mean Amplitude of glycemic excursions: MAGE	—

Secondary

Measure	Time frame
1) M-value 2) glucose area under the curve (over 180mg/dl and below 70mg/dl) 3) fasting plasma glucose, HbA1c, glycoalbumin, 1.5AG 4) beta cell function 5) several biomarkers 6) body weight, Body Mass Index 7) blood pressure 8)multiple regression analysis 9)insulin dose	—

Countries

Japan

Contacts

Public ContactHideaki Miyoshi

Hokkaido University Hospital Department of Internal Medicine II

hidemiyoshi2003@yahoo.co.jp011-706-5915

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026